GSK (NYSE:GSK) Stock Rating Lowered by StockNews.com

GSK (NYSE:GSK) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

Several other brokerages also recently issued reports on GSK. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $33.43 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK has a 1-year low of $32.83 and a 1-year high of $45.92. The company has a market capitalization of $69.29 billion, a price-to-earnings ratio of 21.71, a PEG ratio of 1.54 and a beta of 0.64. The business has a 50-day moving average of $35.75 and a 200-day moving average of $38.99.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On GSK

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC grew its stake in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC lifted its stake in GSK by 14.3% during the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares during the last quarter. Cerity Partners LLC boosted its holdings in GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after buying an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC grew its position in GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after buying an additional 83,433 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.